Venus Remedies gets marketing approval for anticoagulant drug in Saudi Arabia
Venus Remedies on Monday said it has received approval to market a drug, which prevents blood clots, in Saudi Arabia. The company has received the marketing approval for Enoxaparin in pre-filled syringes, the drug firm said in a statement on Monday. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - August 28, 2023 Category: Pharmaceuticals Source Type: news
Venus Remedies gets good manufacturing certification from Saudi drug regulator
The Saudi Food and Drug Authority (SFDA) granted the certification which includes first-time approval for pre-filled enoxaparin syringes and general injection facilities, the company said in a regulatory filing. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - February 27, 2023 Category: Pharmaceuticals Source Type: news
Massive intentional enoxaparin overdose managed with minimal protamine: a single case report - de Olano J, Howland MA, Su MK.
DISCLAIMER: In an effort to expedite the publication of articles, AJHP is posting manuscripts online as soon as possible after acceptance. Accepted manuscripts have been peer-reviewed and copyedited, but are posted online before technical formatting and au... (Source: SafetyLit)
Source: SafetyLit - February 20, 2023 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news
Apixaban Noninferior to Enoxaparin for Postoperative VTE Prophylaxis
Fewer compliance events seen with apixaban versus enoxaparin for extended - duration VTE prophylaxis after abdominopelvic oncologic surgery (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - September 27, 2022 Category: Cancer & Oncology Tags: Internal Medicine, Oncology, Pharmacy, Surgery, Urology, Journal, Source Type: news
Apixaban Noninferior to Enoxaparin for Postoperative VTE Prophylaxis
TUESDAY, Sept. 27, 2022 -- Apixaban is noninferior to enoxaparin for extended-duration venous thromboembolic event prophylaxis (EP) after abdominopelvic oncologic surgery, according to a study published in the October issue of The Journal of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 27, 2022 Category: Pharmaceuticals Source Type: news
Stronger Antiplatelet Better for VTE Prophylaxis After Joint Replacement
(MedPage Today) -- Enoxaparin bested aspirin for preventing symptomatic venous thromboembolism (VTE) after total hip or total knee arthroplasty when used without initial anticoagulation in the CRISTAL randomized trial.
These events occurred within... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - August 23, 2022 Category: Cardiology Source Type: news
Government puts curbs on export of Enoxaparin
"The export of Enoxaparin (formulation and API) and intra-venous immunoglobulin (formulation and API) ....has been put under restricted category with immediate effect," the Directorate General of Foreign Trade (DGFT) said in a notification. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - January 10, 2022 Category: Pharmaceuticals Source Type: news
Sandoz, Inc. Issues Nationwide Recall of One Lot of Enoxaparin Sodium Injection, USP 40mg/0.4 mL Due to Temperature Excursion During Shipping
Princeton, NJ, Sandoz Inc. ( “Sandoz”) is initiating a recall of one lot (SAB06761A, Exp 04/2023) of Enoxaparin Sodium Injection, USP 40 mg/0.4 mL Single-Dose Syringes to the consumer level. A portion of lot SAB06761A experienced a temperature excursion during shipment. Enoxaparin Sodium for Injectio (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - December 2, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news
Late-Breaking Phase 2 Data for Investigational Oral Factor XIa Inhibitor Milvexian Suggest Favorable Antithrombotic Profile Across a Wide Range of Doses
This study establishes proof-of-principle for milvexian as a differentiated antithrombotic agent,” said Jeffrey Weitz, M.D., Professor of Medicine & Biochemistry and Biomedical Sciences at McMaster University and Executive Director of the Thrombosis and Atherosclerosis Research Institute.[i] “Furthermore, the consistently low rates of bleeding across a 16-fold range of milvexian doses suggest that it has a wide therapeutic window, which opens the opportunity to explore milvexian across a broad range of patients including those for whom factor Xa inhibitors are underutilized or not indicated.” The trial met both o...
Source: Johnson and Johnson - November 15, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Cadila inks pact with Italian firm to launch generic product in US
The partners plan to launch the product which is a generic version of Sanofi Aventis's Lovenox (Enoxaparin Sodium Injection) in seven dosage strengths in the US, the statement said. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - August 20, 2021 Category: Pharmaceuticals Source Type: news
Abelacimab Prevents VTE After Total Knee Arthroplasty
Single, postoperative IV dose of abelacimab superior to enoxaparin for preventing venous thromboembolism, with no increase in bleeding risk (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - July 26, 2021 Category: Cancer & Oncology Tags: Oncology, Orthopedics, Pharmacy, Surgery, Conference News, Source Type: news
DDMA asks pharmacies to display available stock, cost of COVID-19 drugs prominently
The drugs are Ivermectin tablets, Doxycyclin tablets/capsule, Methyl Prednisolone tablets and injections, Dexamethasone tablets and injections, Budosenide Inhalers and Respules Favipiravir tablets, Apixaban tablets and Enoxaparin Sodium/ Clexane, it said. (Source: The Economic Times)
Source: The Economic Times - May 22, 2021 Category: Consumer Health News Source Type: news
Apotex Corp. Issues Voluntary Nationwide Recall of Enoxaparin Sodium Injection, USP Due to Mislabeling of Syringe Barrel Measurement Markings
Apotex Corp is voluntarily recalling two (2) batches of Enoxaparin Sodium Injection, USP to consumer level due to a packaging error resulting in some syringes barrels containing 150 mg/mL markings (corresponding to 120 mg/0.8mL strength) instead of 100 mg/mL markings (corresponding to 100 mg/mL stre (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - February 3, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news
India considers allowing import of raw material for manufacturing crude heparin
Heparin and its related derivative, the low molecular weight heparin, also known as enoxaparin, is an anticoagulant that has demonstrated its effectiveness in treatment of patients infected with Covid-19 virus during the ongoing pandemic. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - September 2, 2020 Category: Pharmaceuticals Source Type: news
What are the risk factors and effectiveness of prophylaxis for venous thromboembolism in COVID-19 patients?, CEBM
This study identified a paucity of evidence for both the risks factors of VTE and the effectiveness of prophylactic strategies to prevent VTE in COVID-19 patients.
Potential risk factors which were identified for thrombolytic events include older age and higher levels of D-dimer, though the actual threshold for a high level D-dimer varied between studies.
Commonly encountered prophylactic strategies which were; low molecular weight heparin (LMWH) or unfractionned heparin, nadroparin and enoxaparin. A number of studies found that despite prophylaxis there was still a high incidence of thrombolytic complications in COVID-1...
Source: Current Awareness Service for Health (CASH) - July 13, 2020 Category: Consumer Health News Source Type: news
